Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122

Journal of Virology

Volumn 86, Issue 3, 2012, Pages 1382-1393

  Kambara, Hiroto ^a   Fukuhara, Takasuke ^a   Shiokawa, Mai ^a   Ono, Chikako ^a   Ohara, Yuri ^a   Kamitani, Wataru ^a   Matsuura, Yoshiharu ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA; MICRORNA 122; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE REPLICATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; INNATE IMMUNITY; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS PARTICLE; VIRUS REPLICATION;

CELL LINE, TUMOR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEPACIVIRUS; HUMANS; MICRORNAS; POLYMERASE CHAIN REACTION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84857065456     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06242-11     Document Type: Article

References (71)

1. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. 1979. Controlled synthesis of HBsAg in a differentiated human liver carcinomaderived cell line. Nature 282:615-616.
2. Bai S, et al. 2009. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 284:32015-32027.
3. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215-233.
4. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014.
5. Burns DM, D'Ambrogio A, Nottrott S, Richter JD. 2011. CPEB and two poly(A) polymerases control miR-122 stability and p53 mRNA translation. Nature 473:105-108.
6. Castoldi M, et al. 2011. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J. Clin. Invest. 121:1386-1396.
7. Chang J, et al. 2008. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J. Virol. 82:8215-8223.
8. Chang J, et al. 2004. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 1:106-113.
9. Chang KS, Jiang J, Cai Z, Luo G. 2007. Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81:13783-13793.
10. Cormier EG, et al. 2004. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 101:7270-7274.
11. Date T, et al. 2004. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J. Biol. Chem. 279: 22371-22376.
12. Denard B, et al. 2011. The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells. Cell Host Microbe 10:65-74.
13. Ehrhardt M, et al. 18 April 2011. Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies. Hepatology. [Epub ahead of print.]
14. Elmen J, et al. 2008. LNA-mediated microRNA silencing in non-human primates. Nature 452:896-899.
15. Evans MJ, et al. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805.
16. Farci P, et al. 2000. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339-344.
17. Feigelstock DA, Mihalik KB, Kaplan G, Feinstone SM. 2010. Increased susceptibility of Huh7 cells toHCVreplication does not require mutations in RIG-I. Virol. J. 7:44.
18. Feliu A, Gay E, Garcia-Retortillo M, Saiz JC, Forns X. 2004. Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl. 10:1131-1139.
19. Ge D, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
20. Gentzsch J, et al. 2011. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Res. 89:136-148.
21. Gottwein JM, et al. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49: 364-377.
22. Haid S, Windisch MP, Bartenschlager R, Pietschmann T. 2010. Mousespecific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J. Virol. 84:964-975.
23. Henke JI, et al. 2008. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27:3300-3310.
24. Herker E, et al. 2010. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat. Med. 16:1295-1298.
25. Hughes MG, Jr, et al. 2005. HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation. Am. J. Transplant. 5:2504-2513.
26. Huntzinger E, Izaurralde E. 2011. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 12:99-110.
27. Jangra RK, Yi M, Lemon SM. 2010. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J. Virol. 84:6615-6625.
28. Jopling CL, Schutz S, Sarnow P. 2008. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 4:77-85.
29. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-1581.
30. Kato N, et al. 2009. Efficient replication systems for hepatitis C virus using a new human hepatoma cell line. Virus Res. 146:41-50.
31. Lanford RE, et al. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201.
32. Laskus T, et al. 2004. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 127:764-776.
33. Lauring AS, Andino R. 2010. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 6:e1001005.
34. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int. 29(Suppl. 1):74-81.
35. Lin LT, et al. 2010. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J. Virol. 84: 9170-9180.
36. Lindenbach BD, et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
37. Lohmann V, et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
38. Machlin ES, Sarnow P, Sagan SM. 2011. Masking the 5= terminal nucleotides of the hepatitis C virus genome by an unconventional microRNAtarget RNA complex. Proc. Natl. Acad. Sci. U. S. A. 108:3193-3198.
39. Masaki T, et al. 2010. Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription. J. Virol. 84:5824-5835.
40. Miyanari Y, et al. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9:1089-1097.
41. Moradpour D, Penin F, Rice CM. 2007. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5:453-463.
42. Moriishi K, Matsuura Y. 2007. Evaluation systems for anti-HCV drugs. Adv. Drug Deliv. Rev. 59:1213-1221.
43. Moriishi K, Matsuura Y. 2007. Host factors involved in the replication of hepatitis C virus. Rev. Med. Virol. 17:343-354.
44. Moriishi K, Matsuura Y. 2003. Mechanisms of hepatitis C virus infection. Antivir. Chem. Chemother. 14:285-297.
45. Moriishi K, et al. 2010. Involvement of PA28gamma in the propagation of hepatitis C virus. Hepatology 52:411-420.
46. Narbus CM, et al. 2011. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J. Virol. 85:12087-12092.
47. Park JG, et al. 1995. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62:276-282.
48. Pileri P, et al. 1998. Binding of hepatitis C virus to CD81. Science 282: 938-941.
49. Ploss A, et al. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886.
50. Ploss A, et al. 2010. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc. Natl. Acad. Sci. U. S. A. 107: 3141-3145.
51. Randall G, et al. 2007. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. U. S. A. 104:12884-12889.
52. Roberts AP, Lewis AP, Jopling CL. 2011. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res. 39:7716-7729.
53. Russell RS, et al. 2008. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 105:4370-4375.
54. Scarselli E, et al. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025.
55. Seow TK, Liang RC, Leow CK, Chung MC. 2001. Hepatocellular carcinoma: from bedside to proteomics. Proteomics 1:1249-1263.
56. Skalsky RL, Cullen BR. 2010. Viruses, microRNAs, and host interactions. Annu. Rev. Microbiol. 64:123-141.
57. Sumpter R, Jr, et al. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79:2689-2699.
58. Suppiah V, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41: 1100-1104.
59. Tanaka Y, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-1109.
60. Tani H, et al. 2007. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J. Virol. 81: 8601-8612.
61. Targett-Adams P, Boulant S, McLauchlan J. 2008. Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication. J. Virol. 82:2182-2195.
62. Thomas DL, et al. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801.
63. Vannucchi AM, et al. 1993. Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood 82:978-984.
64. Wakita T, et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
65. Walters KA, et al. 2006. Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog. 2:e59.
66. Windisch MP, et al. 2005. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J. Virol. 79: 13778-13793.
67. Wong N, et al. 2005. Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. Clin. Cancer Res. 11:1319-1326.
68. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 103: 2310-2315.
69. Yoneyama M, et al. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-737.
70. Zhong J, et al. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299.
71. Zhu H, et al. 2007. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133:1649-1659.